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Transforming growth factor b1 is a multifunctional
cytokine involved in many aspects of wound healing.
Here we report the effects of both latent and active
transforming growth factor b1 released from genetic-
ally modi®ed keratinocytes on extracellular matrix
expression by dermal ®broblasts in a coculture sys-
tem. Human keratinocytes were genetically modi®ed
with adenovirus containing cDNA for latent trans-
forming growth factor b1 (AdTGF-b1) or active
transforming growth factor b1 (AdTGF-b1223/225) or
LacZ and cultured with human dermal ®broblasts.
Northern blotting for mRNA con®rmed that kerati-
nocytes were successfully transduced with the adeno-
viruses as the cDNA transcripts are smaller than
native transforming growth factor b1 mRNA. An
enzyme-linked immunosorbent assay speci®c for
transforming growth factor b1 demonstrated that the
transforming growth factor b1 produced by the
genetically modi®ed keratinocytes was able to pass
through the membrane separating the two cell layers.
Levels of transforming growth factor b1 were signi®-
cantly higher for both latent (p < 0.0001) and active
(p < 0.0001) transforming growth factor b1 compared
to the LacZ control. Without acid activation of
samples, keratinocytes transduced with the active
transforming growth factor b1 construct exhibited
signi®cantly higher levels of transforming growth
factor b1 than either the latent construct or the LacZ
control (p < 0.0001). The transforming growth factor
b1 produced was biologically active, as shown by the
plasminogen activator inhibitor assay (p < 0.0001).
To demonstrate that transforming growth factor b1
had an effect on underlying ®broblasts, mRNA was
extracted and analyzed using Northern analysis.
Latent transforming growth factor b1 signi®cantly
increased the expression of type I collagen mRNA
(p < 0.05) but did not signi®cantly affect collagenase
mRNA. Active transforming growth factor b1
signi®cantly increased type I collagen mRNA
(p <0.005) while also decreasing collagenase mRNA
(p <0.05). These results illustrate the ability of
increased levels of transforming growth factor b1 to
override the effects of normal keratinocytes on the
behavior of dermal ®broblasts. Key words: adenovirus/
coculture/®broblasts/keratinocytes/transforming growth fac-
tor b1. J Invest Dermatol 119:456±463, 2002
T
ransforming growth factor b1 (TGF-b1) is a multi-
functional growth factor important in the process of
wound healing due to its ®brogenic effects. Five
TGF-b isoforms have been identi®ed to date, with
TGF-b1, TGF-b2, and TGF-b3 being found in
mammals. During wound healing, TGF-b1 stimulates extracellular
matrix (ECM) synthesis and deposition by inducing ®broblasts to
synthesize collagen, ®bronectin, and glycosaminoglycans (Ignotz
and Massague, 1986; Sporn et al, 1987). TGF-b1 also modulates the
expression of proteases and their inhibitors (Edwards et al, 1987;
Overall et al, 1989), acts as a chemoattractant for monocytes
(Wake®eld et al, 1987) and ®broblasts (Postlethwaite et al, 1987),
and enhances neovascularization (Allen et al, 1993).
TGF-b1 is secreted as a latent complex (LTGF-b1) consisting of
a 25 kDa dimeric mature protein and an N-terminal pro-protein
called the latency-associated peptide (LAP) (Tsuji et al, 1990). It has
been suggested that either a conformational change of the latent
complex (Ghahary et al, 1999) or dissociation of LAP from the
mature protein is required for activation of TGF-b1 (Dallas et al,
1994; Okazaki et al, 1995) as the TGF-b1 receptors do not
recognize native LTGF-b1 (Wake®eld et al, 1987). Although the
mechanisms by which TGF-b1 is activated in vivo have not been
fully elucidated, plasmin and cathepsin D are capable of activating
TGF-b1 by cleaving LAP from the mature protein in the
N-terminal region (Lyons et al, 1988, 1990; Sato and Rifkin,
1989; Sato et al, 1990). In vitro, TGF-b1 can be activated by
extremes of pH and heat (80°C for 10 min) and by detergents
(Gleizes et al, 1997). Latency is very important in the regulation of
TGF-b and previous experiments have shown very different
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outcomes depending on the state of the TGF-b1 (Sellheyer et al,
1993; Sime et al, 1997).
Many growth factors require prolonged exposure to the wound
environment before eliciting an effect. Lynch et al (1989)
demonstrated that, in a partial-thickness dermatome wound in
pigs, single topical applications of epidermal growth factor (EGF),
TGF-a, basic ®broblast growth factor (bFGF), insulin-like growth
factor 1 (IGF-1), and platelet-derived growth factor BB did not
accelerate healing. It has also been reported that daily injections of
EGF into polyvinyl alcohol sponges implanted subcutaneously into
rats produced only a small increase in granulation tissue whereas
using slow-release pellets carrying EGF resulted in a signi®cant
increase in granulation tissue volume and organization (Buckley et
al, 1985). The concentration of recombinant growth factors
required to stimulate DNA synthesis or cell migration in vivo is
1000 times higher than that required in vitro (Bennett and Schultz,
1993). This may be due to proteolytic degradation and/or diffusion
of the growth factor from the wound. Thus a potential solution to
this problem seems to be the use of a genetically modi®ed skin
substitute through which a wound healing promoting factor such as
TGF-b1 is released at the wound site. This study was conducted to
achieve the following objectives: (i) to examine the expression of
both latent and active TGF-b1 from genetically modi®ed human
keratinocytes; (ii) to demonstrate that the TGF-b1 produced was
biologically active using a novel sensitive bioassay for TGF-b1
activity, the plasminogen activator inhibitor/luciferase (PAI/L)
assay (Abe et al, 1994); (iii) to study the effect of latent and active
TGF-b1 on the expression of type I collagen and collagenase in
human dermal ®broblasts cocultured with TGF-b1 genetically
modi®ed keratinocytes.
METHODS AND MATERIALS
Adenoviral vectors expressing active TGF-b1, latent TGF-b1, or LacZ as
a control were used in this study. Two recombinant adenoviruses were
kindly provided by Dr. Jack Gauldie (Department of Biology, Health
Sciences Center, McMaster University) (Sime et al, 1997). The AdLacZ
control was obtained from Quantum Biotechnologies, Chaval, Quebec,
Canada. Brie¯y, both recombinant TGF-b1 adenoviruses contain the
cDNA of the coding region of full-length porcine TGF-b1 as described
by Sime et al (1997). The cDNA fragments for latent and active TGF-b1
were 1.5 and 1.1 kb, respectively. Latent TGF-b1 was expressed by the
AdTGF-b1 construct and active TGF-b1 was expressed by the AdTGF-
b1223/225 construct. TGF-b1 was expressed as the spontaneously active
protein by using a mutant in which Cys223 and Cys225 in the TGF-b1
pro-peptide were converted to Ser. This results in the dissociation of the
pro-peptide and secretion of bioactive TGF-b1 (Brunner et al, 1989;
Samuel et al, 1992; Sime et al, 1997). The adenoviruses were ampli®ed
in 293 A cells and titers were estimated from the tissue culture infectious
dose50 (TCID50), so that the multiplicity of infection (MOI) could be
established.
Cell cultures and gene transduction The procedure of Rheinwald
and Green (1975) was used for cultivation of human foreskin
keratinocytes using serum-free keratinocyte medium (KSFM) (Gibco,
Grand Island, NY) supplemented with bovine pituitary extract (25 mg
per ml) and EGF (0.5 ng per ml). Primary cultured keratinocytes at
passages 3±5 were used. To establish the ®broblast cultures normal skin
punch biopsies, obtained from patients undergoing elective
reconstructive surgery, were established in Dulbecco's modi®ed Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), as
previously described (Ghahary et al, 1994). Strains of dermal ®broblasts at
passages 4±6 were used in this study. Keratinocytes were then grown
alone in the upper chamber on a permeable Millicell culture plate insert
(Millipore, Bedford, MA). These inserts have a pore size of 0.4 mm and
are coated with 0.3 mg bovine type I collagen. Dermal ®broblasts were
grown in the lower chamber of the coculture system.
Keratinocytes were plated at a density of 4 3 105 cells per insert and
incubated 24 h. An MOI of 0.5 was used to transduce the keratinocytes
with the adenoviruses overnight. The keratinocytes were washed and the
inserts were placed into empty six-well plates or plates containing 1 3
105 ®broblasts per well and 4 ml fresh medium (49% KSFM, 49%
DMEM, 2% FBS) was added. The cell cultures were then incubated for
48 h and conditioned medium was collected and tested for the presence
of active and latent TGF-b1.
Fibroblast proliferation Cocultures were established as stated above
using two strains of keratinocytes each in combination with two strains
of ®broblasts (four separate experiments). Keratinocytes were transduced
with LacZ, TGF-b1, or AdTGF-b1223/225 prior to coculturing with
®broblasts. Each condition was tested in triplicate. Following a 48 h
incubation, ®broblasts were counted using a Coulter counter (Model
ZM, Coulter Electronics, Bedfordshire, U.K.).
Enzyme-linked immunosorbent assay (ELISA) for TGF-b1 To
determine the concentration of TGF-b1, a sandwich ELISA was used
based on the procedure reported by Danielpour et al (1989). Brie¯y, 96-
well plates were coated with 100 ml per well of mouse monoclonal
antibody to human TGF-b (R&D Systems, Minneapolis, MN) at a
concentration of 1 mg per ml in phosphate-buffered saline (PBS). The
plates were incubated for 3 h at room temperature followed by 16 h at
4°C. After washing twice with PBS±Tween-20 (PBS-T), the plates were
blocked with 1% bovine serum albumin (BSA, crystallized, Sigma) for
60 min at room temperature and washed twice with PBS-T. To activate
TGF-b1, the culture medium was acidi®ed with 12 ml per 500 ml
conditioned medium of 3 N HCl for 15 min at room temperature and
neutralized with 35 ml of 1 M HEPES/5 N NaOH (5:2). One hundred
microliters of the acidi®ed/neutralized samples was added to each well
and the plates were then incubated at 37°C for 1 h. After washing with
PBS-T, the plates were incubated with 100 ml per well of chicken
antihuman TGF-b (R&D Systems) at a concentration of 2.5 mg per ml
for 1 h. After washing ®ve times with PBS-T, the plates were incubated
with alkaline phosphatase-conjugated rabbit antichicken IgG (Sigma) at
room temperature for 1 h followed by washing ®ve times with PBS-T.
After addition of the substrate (o-nitrophenyl phosphate, 1.5 mg per ml,
Sigma), the plates were incubated at room temperature for 1 h and the
optical density was read using a THERMOmax (Molecular Devices,
Menlo Park, CA) microplate reader at a wavelength of 405 nm. Serial
dilutions (0, 125, 250, 625, 1250, to 2500 pg per ml) of recombinant
human TGF-b1 (R&D Systems) were used to prepare a standard curve.
TGF-b1 time course Keratinocytes were plated at 1.5 3 106 cells per
75 cm2 ¯ask. Cells were transduced with an MOI of 0.5 for each
adenovirus or incubated in medium alone. Conditioned medium was
collected every 2 d and replaced with new medium. The TGF-b1
ELISA was performed for each time point. Total TGF-b1 was measured
following acidi®cation and active TGF-b1 was evaluated by measuring
nonacidi®ed samples.
RNA extraction and hybridization Following 48 h incubation,
culture medium was removed and cell layers were lyzed in 2 ml of
guanidinium thiocyanate (GITC) as previously described (Ghahary et al,
1995). Total RNA was extracted by the GITC/CsCl procedure of
Chirgwin et al (1979); 10 mg of total mRNA from each treatment was
separated by electrophoresis and blotted onto nitrocellulose ®lters. Filters
were then baked under vacuum for 2 h at 80°C and prehybridized in a
solution containing 50% formamide, 0.3 M sodium chloride, 20 mM
Tris±HCl (pH 8.0), 1 mM ethylenediamine tetraacetic acid, 1 3
Denhardt's solution (0.02% BSA, Ficoll, and polyvinylpyrrolidone),
0.005% salmon sperm DNA, and 0.005% poly(A) for 3±4 h at 45°C.
Hybridization was performed in the same solution at 45°C for 16±20 h
using cDNA probes for human TGF-b1, type I collagen, collagenase, or
18S ribosomal RNA. The probe for 18S rRNA was used to ensure
equal loading of samples. The probes were labeled with 32P-g-CTP
(DuPont Canada, Streetsville, Mississauga, Ontario, Canada) by nick
translation. Filters were initially washed at room temperature with 2 3
SSC (SSC = 0.15 M sodium chloride, 0.015 M sodium citrate) and 0.1%
sodium dodecyl sulfate (SDS) for 30 min, and then for 20 min at 65°C
in 0.1 3 SSC and 0.1% SDS solution. Autoradiography was performed
by exposing Kodak X-Omat ®lm to the nitrocellulose ®lters at ±70°C in
the presence of an enhancing screen. The cDNA probes for 18S
ribosomal RNA and collagenase were obtained from the American Type
Culture Collection (Rockville, MD). The other cDNA probes were
gifts: TGF-b (Dr. G.I. Bell, Howard Hughes Medical Institute,
Department of Biochemistry and Molecular Biology and Medicine,
University of Chicago, IL) and type I procollagen (Drs G. Tromp, H.
Kuivaniemi, and L. Ala-Kokko, Department of Biochemistry and
Molecular Biology, Jefferson Institute of Molecular Medicine,
Philadelphia, PA).
Luciferase assay for TGF-b1 Conditioned medium was collected
after 48 h and assayed for TGF-b1 bioactivity using mink lung cells
bearing the PAI/L construct (Abe et al, 1994). Mink lung epithelial cells
transfected with this construct (a generous gift from Dr. Daniel Rifkin,
New York University Medical Center, New York, NY) were cultured
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in DMEM supplemented with 10% FBS, L-glutamine (2 mM), penicillin
G (100 U per ml), streptomycin sulfate (100 mg per ml), and
amphotericin B (250 ng per ml). Samples were acid activated (pH 3) for
15 min followed by neutralization. Conditioned medium collected from
TGF-b1 and TGF-b1223/225 transduced cells was also analyzed without
acid activation to determine the relative amount of spontaneously active
TGF-b1. Samples known to contain high concentrations of TGF-b1
were diluted in 0.1% pyrogen-poor BSA (wt/vol) (Pierce, Rockford, IL)
in serum-free DMEM. A standard curve was constructed (0±500 pg per
ml) using recombinant human TGF-b1 (R&D Systems) diluted in 0.1%
BSA in DMEM.
Transfected mink lung epithelial cells were plated at a density of 1.6
3 104 cells per well in 96-well tissue culture plates. The cells were
allowed to attach for 3 h at 37°C in an atmosphere of 5% CO2. The
medium was replaced with conditioned media or standards and incubated
for 14 h at 37°C. Cells were then washed with PBS and lysed using
50 ml of 1 3 cell lysis buffer (Analytical Luminescence, San Diego, CA)
for 20 min at room temperature on a rotating platform. The cell lysates
(45 ml) were then transferred to clear polypropylene scintillation vials
into which 100 ml of both substrate A and B (Analytical Luminescence)
were added and samples were immediately analyzed using the Beckman
LS 6000 TA scintillation counter.
Statistical analysis For ELISA and PAI/L data, the differences
between the LacZ transduced control cells and either AdTGF-b1 or
AdTGF-b1223/225 transduced cells were evaluated using a two-tailed
nonparametric test (alternative Welch t test). Samples were measured in
triplicate. Data are presented as means 6 1 standard deviation. Student's
t test was used for statistical analysis of mRNA results. p-values < 0.05
were considered signi®cant for all statistical tests.
RESULTS
The kinetics of TGF-b1 expression were studied over 12 d.
Conditioned medium was collected every 48 h for ELISA
measurement of active and total TGF-b1. Signi®cantly higher
levels of TGF-b1 were released from keratinocytes transduced with
AdTGF-b1 or AdTGF-b1223/225 compared to the LacZ control at
all times for at least 12 d (Fig 1A). The level of constitutively active
TGF-b1 released from AdTGF-b1223/225 in nonacidi®ed samples
was also signi®cantly higher than with AdTGF-b1 at all times
(Fig 1B).
To determine whether TGF-b1 produced by the transduced
keratinocytes was able to pass through the insert membrane to
in¯uence dermal ®broblasts grown in the lower chamber, medium
was collected from the top and bottom chambers and analyzed
following acid activation using the TGF-b1 ELISA (data not
shown). There was no signi®cant difference in the concentration of
TGF-b1 in the upper and lower chambers. This ®nding shows that
diffusion of TGF-b1 is not impeded by the insert.
TGF-b1 released from keratinocytes was shown to increase
®broblast proliferation. Keratinocytes transduced with either
AdTGF-b1 or AdTGF-b1223/225 signi®cantly increased the prolif-
eration of ®broblasts in the lower chamber compared to the LacZ
control (p < 0.0001) (Fig 2).
To demonstrate that cells transduced with the AdTGF-b1223/225
construct produced enhanced levels of active TGF-b1, whereas
those transduced with the AdTGF-b1 construct did not, active
TGF-b1 was measured by ELISA in samples that were not acidi®ed
(Fig 3). The conditioned medium derived from keratinocytes
transduced with AdTGF-b1223/225 had a high mean level of active
TGF-b1 (731 6 198 and 818 6 265 pg per ml for keratinocytes
alone and keratinocytes cocultured with ®broblasts, respectively)
compared to keratinocytes transduced with AdTGF-b1 (31 6 29
and 36 6 39 pg per ml alone and with ®broblasts, respectively).
The difference between the level of active TGF-b1 from cells
transduced with AdTGF-b1223/225 and those transduced with
AdTGF-b1 was found to be extremely signi®cant (p < 0.0001).
To examine whether the level of protein production is consistent
with TGF-b1 gene expression, TGF-b1 mRNA was analyzed
using northern analysis (Fig 4). Doublet bands were seen in lanes
containing keratinocytes transduced with either AdTGF-b1 or
AdTGF-b1223/225. An increase in endogenous TGF-b1 was also
noted in ®broblasts that were cocultured with the genetically
modi®ed keratinocytes.
The size of the mRNA transcript is smaller for porcine AdTGF-
b1 and AdTGF-b1223/225 compared to endogenous human TGF-
b1. The autoradiograph shows that there are two transcripts present
in keratinocytes that have been transduced with either AdTGF-b1
(appears as a doublet) or AdTGF-b1223/225, whereas only one
transcript was seen in the controls and in ®broblasts (endogenous
TGF-b1 mRNA). This indicates that the keratinocytes were
successfully transduced with the porcine cDNA TGF-b1 constructs
Figure 1. Time course of release of TGF-b1 from genetically
modi®ed keratinocytes. (A) Conditioned medium was collected every
2 d and total TGF-b1 was measured using an ELISA following
acidi®cation. Compared to the LacZ control (squares), signi®cantly more
TGF-b1 was released from AdTGF-b1 (circles) and AdTGF-b1223/225
(triangles) (*p < 0.0001, **p < 0.001). (B) Constitutively active TGF-b1
was measured in nonacidi®ed samples. Signi®cantly more active TGF-b1
was released from AdTGF-b1223/225 (black bar) than AdTGF-b1 (open bar)
at all times (p < 0.0001, n = 3).
Figure 2. TGF-b1 released from genetically modi®ed
keratinocytes increases the proliferation of dermal ®broblasts.
Four separate experiments were performed with different cell strains.
LacZ was normalized (LacZ = 1) for all experiments. There was a
signi®cant increase in ®broblast proliferation in the presence of AdTGF-
b1 or AdTGF-b1223/225 compared to the LacZ control (*p < 0.0001).
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and that the ®broblasts in coculture with the transduced
keratinocytes were not subsequently infected by adenovirus. Each
blot was probed with a cDNA speci®c for 18S rRNA as a loading
control.
To compare the levels of total TGF-b1 released by the
keratinocytes transduced by the latent and active constructs,
samples were acidi®ed and total TGF-b1 was measured in medium
from keratinocytes alone (Fig 5A) and those cocultured with
dermal ®broblasts (Fig 5B).
The concentration of total TGF-b1 in conditioned medium
from AdTGF-b1 and AdTGF-b1223/225 transduced keratinocytes
both alone and cocultured with ®broblasts was signi®cantly higher
than that from the AdLacZ transduced keratinocyte control (p
< 0.0001). Keratinocytes alone transduced with AdTGF-b1 and
cocultured with ®broblasts exhibited signi®cantly higher levels of
total TGF-b1 compared to those transduced with AdTGF-b1223/
225.
In order to examine whether the TGF-b1 released from
transduced keratinocytes was biologically active, the PAI/L assay
was performed. Following acid activation, the relative concentra-
tions of total TGF-b1 followed the same trends as those seen by
ELISA, both for keratinocytes alone (Fig 6A) and for cocultures of
keratinocytes with ®broblasts (Fig 6B).
In general, the level of total TGF-b1 released from latent
TGF-b1 transduced cells was markedly higher than from AdTGF-
b1223/225 transduced keratinocytes. As shown in Fig 7, however,
without acidi®cation, the biologic activity of AdTGF-b1223/225
transduced keratinocytes was signi®cantly higher than both the
LacZ control (p < 0.0001) and AdTGF-b1 (p < 0.0001).
To demonstrate whether TGF-b1 could affect the ®broblasts in
the lower chamber, total RNA was extracted and analyzed by
northern analysis. The results show that ®broblasts cultured with
latent TGF-b1 transduced keratinocytes exhibited a signi®cant
increase in type I collagen mRNA (p < 0.05) (Fig 8A, B)
compared to the LacZ control. The expression of collagenase
mRNA was not signi®cantly altered in response to latent TGF-b1
(Fig 9A, B).
To quantify the expression of collagenase and type I collagen
mRNA, the intensity of signals was evaluated by densitometry
using 18S rRNA as a loading control. The level of mRNA
between experiments was normalized using the LacZ control and
results for each experimental group were expressed as a percentage
of the LacZ control. On the other hand, ®broblasts cocultured with
keratinocytes transduced with the active TGF-b1 construct had
signi®cantly higher levels of type I collagen mRNA (p < 0.005)
(Fig 8A, B) as well as signi®cantly lower levels of collagenase
mRNA (p < 0.05) (Fig 9A, B) compared to the LacZ control.
Figure 3. TGF-b1 released from keratinocytes transduced with
AdTGF-b1223/225 was constitutively active. Active TGF-b1 was
measured in conditioned medium, which had not been acid activated.
Signi®cantly more TGF-b1 was released from keratinocytes transduced
with the active construct (AdTGF-b1223/225) than from keratinocytes
transduced with the latent construct (AdTGF-b1) (*p < 0.0001). This
difference was observed both for keratinocytes cultured alone and for
keratinocytes cocultured with dermal ®broblasts (four separate
experiments).
Figure 4. Keratinocytes transduced with either AdTGF-b1 or
AdTGF-b1223/225 express a smaller TGF-b1 mRNA transcript
compared to endogenous TGF-b1 mRNA. Representative northern
analysis for TGF-b1 mRNA: keratinocytes cultured alone, lanes 1±4;
keratinocyte mRNA following coculture with ®broblasts, lanes 5±8; and
®broblast mRNA cultured alone and following coculture with
keratinocytes, lanes 9±13. 18S rRNA was used as a loading control. The
TGF-b1 mRNA resulting from the adenoviral constructs is smaller than
native mRNA. Two bands were observed in keratinocytes transduced
with AdTGF-b1 (lanes 3 and 7) and AdTGF-b1223/225 (lanes 4 and 8).
Untreated keratinocytes (lanes 1 and 5), keratinocytes transduced with
the LacZ control (lanes 2 and 6), and ®broblasts under all conditions
(lanes 9±13; F, F/K, F/K + LacZ, F/K + latent, F/K + active) showed
only one TGF-b1 mRNA band.
Figure 5. Total TGF-b in conditioned medium following
acidi®cation. (A) Keratinocytes cultured alone were either untreated
(K), or transduced with LacZ, AdTGF-b1, or AdTGF-b1223/225. (B)
Fibroblasts alone and cocultured with keratinocytes that were either
untreated (F) or transduced with LacZ, AdTGF-b1, or AdTGF-b1223/
225. Keratinocytes transduced with either AdTGF-b1 or AdTGF-b1223/
225 had signi®cantly higher levels of TGF-b1 compared to the LacZ
control (*p < 0.0001). Keratinocytes transduced with AdTGF-b1
had signi®cantly higher levels of total TGF-b1 compared to AdTGF-
b1223/225 (**p < 0.0001) (four separate experiments).
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DISCUSSION
The purpose of this study was to establish a keratinocyte/®broblast
coculture system in which keratinocytes release either active or
latent TGF-b1. In this system, the effects of latent and active
TGF-b1 on underlying ®broblasts can be examined. Replication
de®cient adenoviruses were used to transduce human keratinocytes.
Adenovirus was chosen because of its capacity to transduce both
replicating and nonreplicating cells and the consequent high
ef®ciency of gene transfer. Unlike retroviruses, which may cause
insertional mutagenesis, adenoviral replication occurs episomally,
i.e., outside the host cell nucleus. Gene therapy with adenoviruses
may be preferred to recombinant TGF-b1 protein therapy due to
the relative expense and short half-life of the protein (Bowen-Pope
et al, 1984; Wake®eld et al, 1990). Keratinocytes turn over rapidly
and, if an undesirable outcome occurs in vivo, the epidermis can be
removed (Vogel, 1993). Also, adenoviruses do not integrate into
the host cell genome and are eventually lost through cell
replication. The transient nature of this system is preferred as the
gene product will be expressed during wound healing and will be
undetectable as wound closure is completed.
Numerous studies have used TGF-b1 in the context of wound
healing. TGF-b1 has been applied as a recombinant protein
(Roberts et al, 1986; Puolakkainen et al, 1995), naked cDNA (Benn
et al, 1996), in viral vectors (Sime et al, 1997; Ghahary et al, 1998),
and expressed by transgenic mice (Sellheyer et al, 1993; Chui et al,
1995; Chan et al, 2002). The system used for delivery of TGF-b1
will have a signi®cant effect on the level and duration of protein
expression. This in turn will determine the extent of the in¯uence
on formation of ECM during wound healing.
Figure 6. The biologic activity of total TGF-b1 was measured
using the PAI/L assay following acidi®cation of conditioned
medium. (A) Keratinocytes cultured alone (K, transduced with LacZ,
AdTGF-b1, or AdTGF-b1223/225). (B) Fibroblasts alone or cocultured
with keratinocytes. Keratinocytes transduced with both AdTGF-b1 and
AdTGF-b1223/225 had signi®cantly higher levels of biologically active
TGF-b1 compared to the LacZ control (*p < 0.0001) (two separate
experiments).
Figure 7. The biologic activity of active TGF-b1 was measured
using the PAI/L assay without acid activation. Keratinocytes
transduced with AdTGF-b1223/225 and cultured alone and in coculture
with ®broblasts released signi®cantly higher levels of functional TGF-b1
than the LacZ controls (* p < 0.0001). Keratinocytes transduced with
AdTGF-b1 and cultured alone also had a signi®cantly higher level of
functional TGF-b1 than keratinocytes transduced with LacZ
(**p < 0.001) (two separate experiments).
Figure 8. Expression of type I collagen mRNA by dermal
®broblasts cocultured with genetically modi®ed keratinocytes. (A)
Total RNA was extracted and probed for type I procollagen mRNA by
northern analysis. The autoradiogram shown is representative of four
separate experiments, demonstrating the pattern of 5.8 kb and 4.8 kb
transcripts (top) corresponding to pro-a(I) procollagen mRNA. The
bottom autoradiogram shows the pro®le of the 18S ribosomal RNA used
as a control for loading, obtained by rehybridization of the same blot.
(B) Densitometry was performed and the relative intensity of pro-a(I)
procollagen mRNA to 18S rRNA was calculated; the graph shows
combined data from four experiments. Results for each treatment were
expressed as a percentage of the LacZ control (lane 3). Lanes 1 and 2 in
panel A correspond to F and F/K. Fibroblasts exposed to AdTGF-b1
(lane 4) and AdTGF-b1223/225 (lane 5) had signi®cantly higher levels of
pro-a(I) procollagen compared to the LacZ control (*p < 0.05 and
**p < 0.005, respectively; n = 4).
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The concentration of TGF-b1 required to stimulate collagen and
elastin production in vitro has been established as 10 ng per ml
(Davidson et al, 1993). It is expected that in vivo at least 10 times this
concentration will be required to get a similar rise in ECM proteins
due to the potential lack of bioavailability of TGF-b1 in this
complex system. This very high concentration of growth factor
would be very dif®cult to sustain over a period of days or perhaps
weeks until the wound is healed. An adenoviral vector might
enable high levels of protein to be expressed, however, and the
appropriate concentrations could be determined by adjusting the
infectious dose of the virus.
We have demonstrated that the adenoviruses are capable of
transducing the human keratinocytes without infecting the under-
lying dermal ®broblasts. We were able to show that both the latent
and active forms of TGF-b1 were produced and were biologically
active. The TGF-b1 released by keratinocytes was able to traverse
the membrane insert in the coculture system and affect the
underlying ®broblasts. Interestingly, in addition to changes in
®broblast collagen and collagenase mRNAs, we also noted
autoinduction of TGF-b1 mRNA in ®broblasts cocultured with
the genetically modi®ed keratinocytes (Fig 4). Others have shown
that TGF-b1 can induce its own positive feedback loop (Van
Obberghen-Schilling et al, 1988; Kim et al, 1990; Lin et al, 1995;
Seder et al, 1998).
The effects of normal keratinocytes on dermal ®broblasts have
been reported. Keratinocytes and keratinocyte-conditioned media
have been shown to increase ®broblast proliferation while
decreasing collagen synthesis. It has been postulated that keratino-
cytes may either decrease ®broblast production of collagen or
increase production of collagenase or another metalloproteinase, or
that keratinocytes may decrease the production of a proteinase
inhibitor (Garner, 1998).
TGF-b1 has been shown to increase collagen synthesis (Roberts
et al, 1986; Ghahary et al, 1998) by dermal ®broblasts in culture. It is
not clear, however, whether TGF-b1 can increase the synthesis of
ECM proteins in the presence of other cytokines and growth
factors released by keratinocytes. Here we demonstrate that
culturing ®broblasts with keratinocytes reduces the level of type I
collagen mRNA compared to ®broblasts alone, and that the levels
can be restored by TGF-b1. We have also observed signi®cant
changes in collagenase mRNA with active TGF-b1. Fibroblasts
alone express very little collagenase mRNA, but after coculture
with keratinocytes, collagenase mRNA is greatly upregulated.
With active TGF-b1 treatment, levels are signi®cantly decreased
although not to the level seen in ®broblasts alone. This may be due
to the in¯uence of keratinocyte derived cytokines, which TGF-b1
alone may not be able to abrogate. Edwards et al (1987) had shown
that TGF-b1 was capable of reducing the induction of collagenase
expression by EGF or bFGF to control levels, where the effect was
most pronounced in the presence of other growth factors as
opposed to TGF-b1 alone.
The extent to which TGF-b1 is able to elicit an effect on the
wound depends on its activation. Latent TGF-b1 cannot usually
bind to its receptor unless it is ®rst released from the LAP or a
conformational change occurs. As many cell types possess TGF-b1
receptors, activation of latent TGF-b1 is an important regulatory
step for the function of TGF-b1 in vivo. In vitro, it has been
demonstrated that the close proximity of two different cell types
can result in activation (Dennis and Rifkin, 1990). Latent TGF-b1
has been shown to bind to M6P/IGF-II receptors on cell surfaces
via the phosphorylated glycosylation sites on the LAP and this
binding is inhibited by M6P (Purchio et al, 1988). Ghahary et al
(1999) demonstrated that the ability of different cell types to
activate latent TGF-b1 varies with the number of M6P/IGF-II
receptors. By using 125I-labeled IGF-II, the M6P/IGF-II receptors
on ®broblasts and mink lung epithelial cells were quanti®ed.
Signi®cantly more were present on ®broblasts and only the
®broblasts and not the Mu1Lu cells responded to latent TGF-b1.
In this study, we performed four separate groups of experiments,
each with a different ®broblast cell strain. Each of the cell strains
showed an increase in the expression of type I collagen mRNA
compared to the LacZ control in response to both active and latent
TGF-b1. Although only a very small proportion of latent TGF-b1
was activated in culture (Fig 3), this may have been suf®cient to
elicit an increase in type I collagen mRNA. The differences in the
®brogenic outcomes of these two growth factor states was apparent
in a study of lung ®brosis using both active and latent TGF-b1
(Sime et al, 1997). The transgene was introduced to the rat lungs
using adenoviral vectors; the TGF-b1 protein peaked at day 7 and
declined rapidly by day 14. Overexpression of active TGF-b1 and
not latent TGF-b1 resulted in prolonged interstitial ®brosis. Active
TGF-b1 caused the deposition of collagen, ®bronectin, and elastin
as well as the differentiation of ®broblasts into myo®broblasts. Sime
et al (1997) did not see an increase in hydroxyproline synthesis with
the latent construct, which may be due to the increased complexity
of their in vivo system compared to our in vitro culture system and
also to the different cell types involved. The latent TGF-b1 that
was activated in vivo may diffuse from the wound area, be degraded
by proteinases or interact with TGF-b1 binding proteins such as
a2-macroglobulin, and be cleared from the tissue.
Chan et al (2002) developed a transgenic mouse model by
targeting latent TGF-b1 to the epithelium using a K14 promoter.
Figure 9. Expression of collagenase mRNA by dermal ®broblasts
cocultured with genetically modi®ed keratinocytes. (A) Total
RNA was extracted and probed for collagenase mRNA by northern
analysis. The autoradiogram shown is representative of three separate
experiments, demonstrating the 2.1 kb transcript (top) corresponding to
collagenase mRNA. The bottom autoradiogram shows the pro®le of the
18S ribosomal RNA used as a control for loading, obtained by
rehybridization of the same blot. (B) Densitometry was performed and
the relative intensity of pro-a(I) procollagen mRNA to 18S rRNA was
calculated. The graph shows combined data from three experiments,
with the results of each treatment expressed as a percentage of the LacZ
control (lane 3). Lanes 1 and 2 correspond to F and F/K. Fibroblasts
exposed to AdTGF-b1 (lane 4) did not have signi®cantly lower levels of
collagenase mRNA compared to the control, whereas those exposed to
AdTGF-b1223/225 (lane 5) did (p < 0.05*).
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The study demonstrated a signi®cantly higher level of type I
collagen mRNA in both homozygous and heterozygous animals
versus normal controls at day 9 following a full-thickness punch
biopsy wound. This difference coincided with signi®cantly higher
levels of total TGF-b1 as measured by the PAI/L assay. One of the
most obvious differences in healing in the transgenic animals was
the delay in reepithelialization compared to normal animals, which
may be due to TGF-b1 directly inhibiting keratinocyte prolifer-
ation (Shipley et al, 1986). Reepithelialization may also be affected
as a result of TGF-b1 diminishing keratinocyte migration by
decreasing the expression of collagenase. Keratinocytes rely upon
the release of metalloproteinases in order to break down ECM so
that they may migrate across granulation tissue and dissect eschar
from viable tissue (Pilcher et al, 1997).
In summary, the model we used allows for a direct comparison of
the effects of latent and active TGF-b1 on dermal ®broblasts
cocultured with genetically modi®ed keratinocytes. As the wound
environment contains elements required for the activation of latent
TGF-b1, the use of latent TGF-b1 genetically modi®ed keratino-
cytes in the form of either sheets of keratinocytes or a keratinocyte/
®broblast skin substitute should be advantageous over the use of
active TGF-b1. In this way, the activation of TGF-b1 is limited to
the wound area and the risk of development of ®brosis in other
organs due to possible leakage of latent TGF-b1 is minimal.
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